News

Aethlon Medical Explores Hemopurifier's Role Against H5N1 Flu

Aethlon Medical Explores Hemopurifier's Role Against H5N1 Flu

Aethlon Medical Explores the Hemopurifier's Potential Against H5N1

Aethlon Medical, Inc. (Nasdaq: AEMD) is focused on advancing medical technologies that aim to treat severe illnesses, particularly those caused by infectious diseases like the avian influenza H5N1, commonly known as Bird Flu. Recent developments have prompted the company to share insights about its investigational device, the Hemopurifier, and its capabilities in combating such threats.

The Rising Concern of H5N1 Influenza

The emergence of H5N1 in livestock and reports of human infections have raised serious health concerns among authorities. The isolation of H5N1 in dairy cows and reported cases in humans across various regions highlight the need for effective interventions. Aethlon has received numerous inquiries about the Hemopurifier's ability to deal with these situations.

How the Hemopurifier Works

The Hemopurifier is a clinical stage medical device designed to filter out enveloped viruses and other harmful particles from the bloodstream. Utilizing advanced technologies involving plasma separation, size exclusion, and affinity binding, the device targets viruses that possess sugar molecules like mannose on their surface. This is crucial for the Hemopurifier's functionality, especially with viruses like H5N1.

Successful In Vitro Studies

Aethlon Medical has previously partnered with Battelle labs to investigate the effectiveness of the Hemopurifier on H5N1 via in vitro testing. In these studies, the device was able to successfully remove 99% of the H5N1 virus from circulating samples after six hours of treatment, demonstrating significant potential for future application.

The Device's Clinical Applications

While the Hemopurifier has not yet been used on patients suffering from H5N1, it has shown promising results in treating other life-threatening infections. To date, the device has been utilized in 38 patients across 164 treatment sessions targeting serious conditions such as hepatitis C, HIV, COVID-19, and even Ebola. This diverse application underscores its potential effectiveness in managing severe viral infections.

FDA Designation and Future Monitoring

The Hemopurifier is recognized by the FDA as a “breakthrough device” aimed at addressing critical viral infections for which no adequate treatment exists. Given the current state of emergency declared in some regions related to H5N1, Aethlon plans to closely monitor developments in the landscape and engage with healthcare providers to prepare for potential future interventions.

Aethlon Medical: Leaders in Innovative Medical Solutions

Aethlon Medical is dedicated to revolutionizing treatment options for severe diseases through innovative technologies. The Hemopurifier exemplifies their commitment to addressing life-threatening conditions by efficiently capturing harmful viruses. Extensive research and successful clinical outcomes have propelled Aethlon’s standing as a pioneer in therapeutic solutions. By harnessing proprietary technology, the company continues to explore new frontiers in healthcare.

Frequently Asked Questions

What is the Hemopurifier device?

The Hemopurifier is an investigational medical device designed to filter and remove enveloped viruses from the bloodstream, thus aiming to treat serious viral infections.

How effective is the Hemopurifier against H5N1?

In laboratory tests, the Hemopurifier has been shown to remove 99% of H5N1 virus, indicating a strong potential for treating this infection in a clinical setting.

Has the Hemopurifier been used in clinical settings?

Yes, the Hemopurifier has been used in various clinical sessions targeting diseases like hepatitis C, HIV, and others, demonstrating its versatile application.

What regulatory status does the Hemopurifier have?

The Hemopurifier has received “breakthrough device” designation from the FDA, allowing for expedited development and review processes for critical medical devices.

What future developments should we expect from Aethlon Medical?

Aethlon Medical plans to monitor the situation regarding H5N1 closely and adapt its strategy as needed, engaging with healthcare providers to offer potential treatments for serious infections.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 33

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Voranigo Follow-Up Deepens the Glioma Care Debate Today

Updated Category News Views 136

Brain-tumor progress rarely arrives with a clean victory lap, but the longer INDIGO readout gives clinicians and sector watchers something sturdier than a one-time headline. Servier presented extended Phase 3 results for VORANIGO, or vorasidenib, at the Society for Neuro-Oncology meeting in Philadelphia on November 14 and 15, 2026. The central message is durable benefit...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 112

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 196

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
Dolby's Strong Quarter Meets a Flat 2027 Reality Check

Updated Category News Views 67

A licensing machine just coughed up a very good quarter, then told investors not to expect the engine to accelerate next year. That is the whole Dolby story in one uncomfortable breath. NYSE:DLB finished fiscal 2026 with fourth-quarter revenue of $374 million, up from $307 million a year earlier, while GAAP diluted earnings climbed to $0.86 from $0.51. Those are not...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 184

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 0

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 99

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Vusion Lands a 2,000-Store dm EdgeSense Rollout in Germany

Updated Category News Views 108

A drugstore shelf rarely gets anyone's pulse racing, but 2,000 of them wired into a live digital system is a serious retail deployment. Vusion has expanded its partnership with dm-drogerie markt to roll out its newest EdgeSense platform across about 2,000 German stores over the next three years. This is not a glossy one-store pilot with a ribbon-cutting and a few tablets...

Continue Reading

Top 5 Most Recently Viewed Articles

Rocket Companies Faces Turmoil Amid Zillow's Earnings Shock

Updated Category News Views 212

Rocket Companies Stock Falls After Market Reactions Rocket Companies Inc (NYSE: RKT) is experiencing a downward trend as investors reassess their positions in housing-related stocks. This comes in the wake of a notable sell-off linked to Zillow Group Inc's disappointing earnings report, alongside growing trepidation surrounding artificial intelligence's impact on the real...

Continue Reading
Understanding Dimensional Fund Advisors Ltd.'s Recent Disclosure Actions

Updated Category News Views 139

Introduction to Dimensional Fund Advisors Ltd. Dimensional Fund Advisors Ltd. stands as a prominent investment management firm that focuses on providing high-quality investment solutions. Known for its innovative strategies, the firm has made significant strides in the financial sector. Public Opening Position Disclosure The recent public opening position disclosure by...

Continue Reading
Challenges Ahead for Dunxin Financial Following Delisting

Updated Category News Views 154

Understanding Dunxin Financial's Delisting Process NEW YORK - NYSE American LLC has initiated delisting proceedings for Dunxin Financial Holdings Limited, identified by the ticker symbol DXF for its American depositary shares (ADSs). This move by NYSE Regulation follows a determination that Dunxin Financial's shares do not meet the necessary listing standards, mainly due...

Continue Reading
Pro Music Rights Gains Official Approval as PRO in US Market

Updated Category News Views 198

Pro Music Rights Officially Recognized as a Performing Rights Organization Music Licensing, Inc. (OTC: SONG) has recently celebrated a significant milestone with the official recognition of its wholly-owned subsidiary, Pro Music Rights (PMR), as a Performing Rights Organization (PRO). This acknowledgment, appearing in the Federal Register, elevates PMR’s status in the...

Continue Reading
Dentsply Sirona Welcomes Aldo M. Denti as CCO to Innovate Sales

Updated Category News Views 206

Dentsply Sirona Appoints New Chief Commercial Officer Dentsply Sirona Inc. (NASDAQ: XRAY) has made a significant move to strengthen its commercial strategies by appointing Aldo M. Denti as its new Executive Vice President and Chief Commercial Officer. This change signals a commitment to enhancing customer experience and streamlining operations within the company....

Continue Reading